{"id":13568,"date":"2011-01-28T08:30:00","date_gmt":"2011-01-28T07:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/4-trimestre-2010\/"},"modified":"2011-01-28T08:30:00","modified_gmt":"2011-01-28T07:30:00","slug":"4-trimestre-2010","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/4-trimestre-2010\/","title":{"rendered":"4th quarter 2010"},"content":{"rendered":"

<\/font><\/font><\/strong><\/p>\n

<\/font><\/font><\/strong><\/p>\n

<\/font><\/font><\/strong><\/p>\n

<\/font><\/font><\/strong><\/p>\n

Novartis: 2010 results in line with forecasts<\/p>\n

<\/font><\/font><\/strong><\/p>\n

( Les Echos online \u2013 27\/01\/2011 , The Financial Times online \u2013 27\/01\/2011 ) <\/p>\n

<\/font><\/font><\/span><\/p>\n

For 2010, Novartis delivered results in line with forecasts. Profit rose 18% to $9.97bn versus $9.72bn expected. Turnover increased by 14% to 50.6 billion, in line with the estimated 50.54. Pharmaceutical sector sales decreased by 7% to $30.56bn. In the 4th quarter, net income fell by 2% to $2.27bn, turnover increased by 10% to $14.2bn and pharmaceutical division sales reached $8.03bn, +10%.<\/p>\n

<\/font><\/font><\/p>\n

AstraZeneca: 4th quarter 2010 better than expected<\/p>\n

<\/font><\/font><\/strong><\/p>\n

( Les Echos online \u2013 27\/01\/2011 ) <\/p>\n

<\/font><\/font><\/p>\n

AstraZeneca recorded quarterly results higher than expected, thanks also to the good performance of the anti-cholesterol Crestor (rosuvastatin). The turnover, in the 4th quarter of 2010, reached 8.62 billion dollars compared to the expected 8.38. Earnings per share were $1.39 per share, up 1%.<\/p>\n

<\/font><\/font><\/p>\n

FY2010 slowdown for J&J<\/p>\n

<\/font><\/font><\/strong><\/p>\n

( The Financial Times online \u2013 01\/25\/2011 , The New York Times online \u2013 01\/25\/2011 , The Wall Street Journal online \u2013 01\/25\/2011 , The New York Times Pag.B2 \u2013 01\/26\/2011 , Finance & Markets Pag.10 \u2013 26\/01\/2011 , The Wall Street Journal Europe Pag.21 \u2013 26\/01\/2011 , Il Sole 24 Ore Finance & Markets Pag.38 \u2013 26\/01\/2011 , MF- Milano Finanza Pag. .5 \u2013 26\/01\/2011 , The Financial Times Pag.26 \u2013 26\/01\/2011 , Les Echos online \u2013 26\/01\/2011 ) <\/p>\n

<\/font><\/font><\/span><\/p>\n

Recent market recalls of certain products, mainly for children, have impacted Johnson & Johnson's 4th quarter 2010 accounts. Profits decreased by 12% to 1.9 billion dollars, compared to the 2.2 recorded in 2009 mainly due to the drop in sales (-8.1%) in the USA. For the full year 2010, J&J reported earnings growth of 8.7% to $13.3B and revenues decline of 0.5% to $61.6B. On Wall Street the<\/p>","protected":false},"excerpt":{"rendered":"

Novartis: risultati 2010 in linea con le previsioni ( Les Echos online – 27\/01\/2011 , The Financial Times online – 27\/01\/2011 ) Per il 2010 Novartis ha realizzato risultati conformi alle previsioni. Il profitto è cresciuto del 18% a 9,97 mld di dollari, rispetto ai 9,72 previsti. Il giro d’affari è aumentato del 14% a …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-13568","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=13568"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13568\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=13568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=13568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=13568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}